Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Liver Pathology

Gastroenterology Clinics of North America

Volumn 46, Issue 2, 2017, Pages 327-343

  Sonderup, Mark W ^a   Wainwright, Helen Cecilia ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Coinfections; Drug induced liver injury; HIV; Low high income countries; Obesity

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ANTIRETROVIRAL THERAPY; CAUSE OF DEATH; DRUG EFFICACY; HEPATITIS B; HEPATITIS C; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION CONTROL; LIVER TOXICITY; MIXED INFECTION; REVIEW; TOXIC HEPATITIS; BIOPSY; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPLICATION; LIVER; MICROBIOLOGY; PATHOLOGY;

ANTI-RETROVIRAL AGENTS; BIOPSY; CHEMICAL AND DRUG INDUCED LIVER INJURY; COINFECTION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTEGRASE INHIBITORS; LIVER; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 85019270907     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2017.01.007     Document Type: Review

References (80)

1. UNAIDS Global Fact Sheet. Available at: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Accessed February 27, 2017.
2. UN AIDS Global AIDS update. 2016. Available at: http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf. Accessed February 27, 2017.
3. Teeraananchai, S., Kerr, S.J., Amin, J., et al. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med, 2016 [Epub ahead of print].
4. Smith, C.J., Ryom, L., Weber, R., et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 384:9939 (2014), 241–248.
5. Shisana, O., Rehle, T., Simbayi, L.C., et al. South African national HIV prevalence, incidence and behaviour survey, 2012. 2014, HSRC Press, Cape Town (South Africa) Available at: http://www.hsrc.ac.za/uploads/pageContent/4565/SABSSM%20IV%20LEO%20final Accessed February 27, 2017.
6. Zumla, A., George, A., Sharma, V., et al. The WHO 2014 global tuberculosis report–further to go. Lancet Glob Health 3:1 (2015), e10–e12.
7. Wood, R., Lawn, S.D., Caldwell, J., et al. Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status. PLoS One, 6(10), 2011, e25098.
8. Matthews, P.C., Geretti, A.M., Goulder, P.J., et al. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in sub-Saharan Africa. J Clin Virol 61:1 (2014), 20–33.
9. Kourtis, A.P., Bulterys, M., Hu, D.J., et al. HIV-HBV coinfection–a global challenge. N Engl J Med 366:19 (2012), 1749–1752.
10. Naggie, S., Sulkowski, M.S., Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 142:6 (2012), 1324–1334.e1323.
11. Falade-Nwulia, O., Seaberg, E.C., Rinaldo, C.R., et al. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis 55:4 (2012), 507–513.
12. Ng, M., Fleming, T., Robinson, M., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384:9945 (2014), 766–781.
13. Poles, M.A., Dieterich, D.T., Schwarz, E.D., et al. Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr Hum Retrovirol 11:2 (1996), 170–177.
14. Cappell, M.S., Schwartz, M.S., Biempica, L., Clinical utility of liver biopsy in patients with serum antibodies to the human immunodeficiency virus. Am J Med 88:2 (1990), 123–130.
15. Kennedy, M., O'Reilly, M., Bergin, C.J., et al. Liver biopsy pathology in human immunodeficiency virus infection. Eur J Gastroenterol Hepatol 10:3 (1998), 255–258.
16. Garcia-Ordonez, M.A., Colmenero, J.D., Jimenez-Onate, F., et al. Diagnostic usefulness of percutaneous liver biopsy in HIV-infected patients with fever of unknown origin. J Infect 38:2 (1999), 94–98.
17. Piratvisuth, T., Siripaitoon, P., Sriplug, H., et al. Findings and benefit of liver biopsies in 46 patients infected with human immunodeficiency virus. J Gastroenterol Hepatol 14:2 (1999), 146–149.
18. Rathi, P.M., Amarapurkar, D.N., Borges, N.E., et al. Spectrum of liver diseases in HIV infection. Indian J Gastroenterol 16:3 (1997), 94–95.
19. Lizardi-Cervera, J., Soto Ramirez, L.E., Poo, J.L., et al. Hepatobiliary diseases in patients with human immunodeficiency virus (HIV) treated with non highly active anti-retroviral therapy: frequency and clinical manifestations. Ann Hepatol 4:3 (2005), 188–191.
20. Sonderup, M.W., Wainwright, H., Hall, P., et al. A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome. Hepatology 61:5 (2015), 1721–1729.
21. Goldin, R.D., Fish, D.E., Hay, A., et al. Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection. J Clin Pathol 43:3 (1990), 203–205.
22. Housset, C., Pol, S., Carnot, F., et al. Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 15:4 (1992), 578–583.
23. Colin, J.F., Cazals-Hatem, D., Loriot, M.A., et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29:4 (1999), 1306–1310.
24. Sonderup, M.W., Wainwright, H., Hairwadzi, H., et al. A clinicopathological comparison of HIV/Hepatitis B co-infection and Hepatitis B mono-infection in Cape Town, South Africa. Hepatology, 48(4), 2008, 1176A.
25. O'Hara, S.P., Small, A.J., Nelson, J.B., et al. The human immunodeficiency virus type 1 tat protein enhances Cryptosporidium parvum-induced apoptosis in cholangiocytes via a Fas ligand-dependent mechanism. Infect Immun 75:2 (2007), 684–696.
26. Bonacini, M., Hepatobiliary complications in patients with human immunodeficiency virus infection. Am J Med 92:4 (1992), 404–411.
27. Cappell, M.S., Hepatobiliary manifestations of the acquired immune deficiency syndrome. Am J Gastroenterol 86:1 (1991), 1–15.
28. Oppenheimer, A.P., Koh, C., McLaughlin, M., et al. Vanishing bile duct syndrome in human immunodeficiency virus infected adults: a report of two cases. World J Gastroenterol 19:1 (2013), 115–121.
29. Hindupur, S., Yeung, M., Shroff, P., et al. Vanishing bile duct syndrome in a patient with advanced AIDS. HIV Med 8:1 (2007), 70–72.
30. Maartens, G., Celum, C., Lewin, S.R., HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 384:9939 (2014), 258–271.
31. Ford, N., Shubber, Z., Meintjes, G., et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV 2:10 (2015), e438–e444.
32. Price, J.C., Thio, C.L., Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol 8:12 (2010), 1002–1012.
33. Chan, D.P., Sun, H.Y., Wong, H.T., et al. Sexually acquired hepatitis C virus infection: a review. Int J Infect Dis 49 (2016), 47–58.
34. Ingiliz, P., Rockstroh, J.K., Natural history of liver disease and effect of hepatitis C virus on HIV disease progression. Curr Opin HIV AIDS 10:5 (2015), 303–308.
35. Lewden, C., May, T., Rosenthal, E., et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The “Mortalite 2000 and 2005” surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 48:5 (2008), 590–598.
36. Mandorfer, M., Schwabl, P., Steiner, S., et al. Advances in the management of HIV/HCV coinfection. Hepatol Int 10:3 (2016), 424–435.
37. Nunez, M., Mendes-Correa, M.C., Viral hepatitis and HIV: update and management. Antivir Ther 18:3 Pt B (2013), 451–458.
38. Smilack, J.D., Trimethoprim-sulfamethoxazole. Mayo Clin Proc 74:7 (1999), 730–734.
39. Gordin, F.M., Simon, G.L., Wofsy, C.B., et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 100:4 (1984), 495–499.
40. O'Brien, J.G., Dong, B.J., Coleman, R.L., et al. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis 24:5 (1997), 854–859.
41. Sousa-Pinto, B., Pinto-Ramos, J., Correia, C., et al. Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01. J Allergy Clin Immunol 136:4 (2015), 1092–1094.e1093.
42. Ogedegbe, A.O., Sulkowski, M.S., Antiretroviral-associated liver injury. Clin Liver Dis 7:2 (2003), 475–499.
43. Brinkman, K., ter Hofstede, H.J., Burger, D.M., et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12:14 (1998), 1735–1744.
44. Chariot, P., Drogou, I., de Lacroix-Szmania, I., et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 30:1 (1999), 156–160.
45. Nunez, M., Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 52:3 (2010), 1143–1155.
46. Birkus, G., Hitchcock, M.J., Cihlar, T., Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46:3 (2002), 716–723.
47. Walker, U.A., Setzer, B., Venhoff, N., Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16:16 (2002), 2165–2173.
48. Vispo, E., Moreno, A., Maida, I., et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 24:8 (2010), 1171–1176.
49. Vispo, E., Morello, J., Rodriguez-Novoa, S., et al. Noncirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis 24:1 (2011), 12–18.
50. Mallet, V.O., Varthaman, A., Lasne, D., et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 23:12 (2009), 1511–1518.
51. Schiano, T.D., Kotler, D.P., Ferran, E., et al. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 102:11 (2007), 2536–2540.
52. Dieterich, D.T., Robinson, P.A., Love, J., et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 38:Suppl 2 (2004), S80–S89.
53. Wooltorton, E., HIV drug nevirapine (Viramune): risk of severe hepatotoxicity. CMAJ, 170(7), 2004, 1091.
54. Terelius, Y., Figler, R.A., Marukian, S., et al. Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact 255 (2016), 31–44.
55. Sulkowski, M.S., Thomas, D.L., Mehta, S.H., et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35:1 (2002), 182–189.
56. Sanne, I., Mommeja-Marin, H., Hinkle, J., et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 191:6 (2005), 825–829.
57. Shubber, Z., Calmy, A., Andrieux-Meyer, I., et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS 27:9 (2013), 1403–1412.
58. Meyer zu Schwabedissen, H.E., Oswald, S., Bresser, C., et al. Compartment-specific gene regulation of the CAR inducer efavirenz in vivo. Clin Pharmacol Ther 92:1 (2012), 103–111.
59. Manosuthi, W., Sukasem, C., Lueangniyomkul, A., et al. CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy. Int J Antimicrob Agents 43:3 (2014), 292–296.
60. Apostolova, N., Gomez-Sucerquia, L.J., Gortat, A., et al. Autophagy as a rescue mechanism in efavirenz-induced mitochondrial dysfunction: a lesson from hepatic cells. Autophagy 7:11 (2011), 1402–1404.
61. Ford, N., Mofenson, L., Shubber, Z., et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 28:Suppl 2 (2014), S123–S131.
62. Sonderup, M.W., Maughan, D., Gogela, N., et al. Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa. AIDS 30:9 (2016), 1483–1485.
63. Qayyum, S., Dong, H., Kovacic, D., et al. Combination therapy efavirenz/emtricitabine/tenofovir disoproxil fumarate associated with hepatic failure. Curr Drug Saf 7:5 (2012), 391–393.
64. Patil, R., Ona, M.A., Papafragkakis, H., et al. Acute liver toxicity due to efavirenz/emtricitabine/tenofovir. Case Reports Hepatol, 2015, 2015, 280353.
65. Cohen, C.J., Molina, J.M., Cahn, P., et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr 60:1 (2012), 33–42.
66. Pozniak, A.L., Morales-Ramirez, J., Katabira, E., et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 24:1 (2010), 55–65.
67. Sulkowski, M.S., Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 38:Suppl 2 (2004), S90–S97.
68. Crabb, C., GlaxoSmithKline ends aplaviroc trials. AIDS, 20(5), 2006, 641.
69. Abel, S., Back, D.J., Vourvahis, M., Maraviroc: pharmacokinetics and drug interactions. Antivir Ther 14:5 (2009), 607–618.
70. Hardy, W.D., Gulick, R.M., Mayer, H., et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 55:5 (2010), 558–564.
71. Song, I.H., Borland, J., Savina, P.M., et al. Pharmacokinetics of single-dose dolutegravir in HIV-Seronegative subjects with moderate hepatic impairment compared to healthy matched controls. Clin Pharmacol Drug Dev 2:4 (2013), 342–348.
72. Meintjes, G., Lawn, S.D., Scano, F., et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 8:8 (2008), 516–523.
73. Muller, M., Wandel, S., Colebunders, R., et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 10:4 (2010), 251–261.
74. Abay, S.M., Deribe, K., Reda, A.A., et al. The effect of early initiation of antiretroviral therapy in tb/hiv-coinfected patients: a systematic review and meta-analysis. J Int Assoc Provid AIDS Care 14:6 (2015), 560–570.
75. Odone, A., Amadasi, S., White, R.G., et al. The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis. PLoS One, 9(11), 2014, e112017.
76. Sonderup, M.W., Wainwright, H., Spearman, C.W., Hepatic tuberculosis-associated immune reconstitution inflammatory syndrome compared to antiretroviral naive HIV positive patients with hepatic tuberculosis. Hepatology, 50(Suppl. 4), 2009, 1246A.
77. Wong, E.B., Omar, T., Setlhako, G.J., et al. Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLoS One, 7(10), 2012, e47542.
78. Rosenthal, E., Salmon-Ceron, D., Lewden, C., et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). HIV Med 10:5 (2009), 282–289.
79. Weber, R., Sabin, C.A., Friis-Moller, N., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166:15 (2006), 1632–1641.
80. Smith, C., Sabin, C.A., Lundgren, J.D., et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 24:10 (2010), 1537–1548.